Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05730023

A Multimodal Approach for Clinical Diagnosis and Treatment of Primary Progressive Aphasia, MAINSTREAM ID:3430931

Primary Progressive Aphasia (PPA) is a syndrome due to different neurodegenerative disorders selectively disrupting language functions. PPA specialist care is underdeveloped. There are very few specialists (neurologists, psychiatrists, neuropsychologists and speech therapists) and few hospitals- or community-based services dedicated to diagnosis and continuing care. Currently, healthcare systems struggle to provide adequate coverage of diagnostic services, and care is too often fragmented, uncoordinated, and unresponsive to the needs of people with PPA and their families. Recently attention has been gained by digital-health technologies, such immunoassay analyzer and high-field MRI, the most promising approaches to increase our understanding of neurodegeneration, and by new non-invasive brain stimulation techniques such as transcranial direct current stimulation (tDCS) that allow a personalized treatment approach. Our goal is to develop a new treatment approach in PPA in which the regional secondary care centers participating in this project should be the hub of a regional network. The MAINSTREAM (WP2- Efficacy of personalized training in the early stage of PPA) looks forward to introduce and evaluate therapeutic innovation such as tDCS coupled with language therapy in rehabilitation settings (WP2 Early Treatment).

This objective will be pursued by conducting a randomized controlled pilot study in order to evaluate the efficacy of a combined treatment of Active (anodal) tDCS and individualized language training compared to Placebo tDCS combined with individualized language training in a subgroup of mild PPA defined using the Progressive Aphasia Severity Scale (PASS) (Sapolsky D, Domoto-Reilly K, Dickerson BCJA. Use of the Progressive Aphasia Severity Scale (PASS) in Monitoring Speech and Language Status in PPA. (2014) 28(8-9):993-1003).

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Primary Progressive Aphasia Alzheimer Disease Aphasia Aphasia, Primary Progressive Behavior Brain Diseases Central Nervous System Diseases Communication Disorders Dementia Language Disorders Mental Disorders Nervous System Diseases Neurobehavioral Manifestations Neurocognitive Disorders Neurodegenerative Diseases Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms Speech Disorders Tauopathies

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Maria Cotelli, Brescia, BS, Italy

Loading trial locations.

About this study

60 patients with PPA will be recruited from IRCCS Istituto Centro San Giovanni di Dio, Fatebenefratelli, Brescia; IRCCS Fondazione Istituto Neurologico Nazionale C. Mondino, Pavia; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan and Fondazione Don Carlo Gnocchi - ONLUS, Milan.

The diagnostic evaluation will include cognitive and language testing, neurologic examination and neuroimaging (Magnetic Resonance Imaging (MRI) or Positron Emission Tomography PET)).

All the patients will undergo five consecutive days a week for two weeks of treatment sessions of 25 minutes:

  • 30 patients will receive Active tDCS over dorsolateral prefrontal cortex-DLPFC (anode over the left DLPFC with the cathode over the right supraorbital region) while performing an individualized language training;
  • 30 patients will receive Placebo tDCS during an individualized language training.

The two groups will be matched for sex, age, education, language severity (as defined in the Frontotemporal Dementia Clinical Dementia Rating subscale), and overall severity according to the FTD Clinical Dementia Rating.

Two trained neuropsychologists will administer the neuropsychological testing at baseline (T0), post-treatment (T1) and 3-months (T2) follow-up. All of assessments will be conducted by the same assessor.

To elucidate the mechanisms underlying tDCS effects, Magnetic Resonance Imaging (MRI) and bimolecular data will be collected at T0 and T1 (after the treatment).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis PPA according to the current clinical criteria (Gorno-Tempini et al., 2011);
  • Mild PPA defined using the Progressive Aphasia Severity Scale (PASS);
  • Italian native speakers.

Exclusion criteria

  • Presence of developmental disorders;
  • Presence of any medical or psychiatric illness that could interfere in completing assessments;
  • Presence of any medical condition that represents a contraindication to tDCS.

Treatment and study plan

active tDCS

Device

Active tDCS (anode will be applied over the left DLPFC with the cathode over the right supraorbital region);

individualized language training

Behavioral

individualized language training

Placebo tDCS

Device

Placebo tDCS (the current will be turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period);

Primary outcomes

  1. Change in measure of naming as assessed by International Picture Naming Project Task (IPNP)

    Time frame: Baseline up to 2 weeks and 3 months

    International Picture Naming Project Task (IPNP): trained (score range: min= 0, max= 32, higher score=better outcome) and untrained object items (score range: min= 0, max= 32, higher score=better outcome); action items (score range: min= 0, max= 60, higher score=better outcome).

Secondary outcomes

  1. Change in measure of quality of life as assessed by Stroke and Aphasia Quality of Life Scale - 39 (SAQoL-39)

    Time frame: Baseline up to 2 weeks and 3 months

    Stroke and Aphasia Quality of Life Scale - 39 (SAQoL-39) is a measure of health-related quality of life in people with long-term aphasia. It provides a total score from 1 to 5 (higher score=better outcome) and it analyzes the following four domains: physical (score range: min= 1, max= 5, higher score=better outcome); psychosocial (score range: min= 1, max= 5, higher score=better outcome); communication (score range: min= 1, max= 5, higher score=better outcome) and energy (score range: min= 1, max= 5, higher score=better outcome).

  2. Change in measure of quality of life as assessed by Communication Outcome After Stroke (COAST)

    Time frame: Baseline up to 2 weeks and 3 months

    Communication Outcome After Stroke (COAST) is a measure of the functional communication in daily activities and of the impact of the quality of life point of view of aphasia patient (COAST total score range: min= 0, max= 80, higher score=better outcome) and their carer (Carer COAST total score range: min= 0, max= 80, higher score=better outcome).

  3. Change in measure of quality of life as assessed by Functional Outcome Questionnaire-aphasia

    Time frame: Baseline up to 2 weeks and 3 months

    Functional Outcome Questionnaire-aphasia is a measure of aphasia's functional and pragmatic communication in home and community settings, It provides a total score from 32 to 160 (higher score=better outcome) and it is divided into four subscales: communicating basic needs (CBN score range: min= 1, max= 35, higher score=better outcome); making routine requests (MRR score range: min= 1, max= 35, higher score=better outcome); communicating new information (CNI score range: min= 1, max= 40, higher score=better outcome) and attention/other communication skills (AO score range: min= 1, max= 50, higher score=better outcome).

  4. Change in dementia severity as assessed by Frontotemporal Dementia- Clinical Dementia Rating Scale (FTD-CDR)- Sum of Boxes

    Time frame: Baseline up to 2 weeks and 3 months

    Frontotemporal Dementia- Clinical Dementia Rating Scale (FTD-CDR)- Sum of Boxes (score range: min= 0, max= 24, higher score=worse outcome).

  5. Change in dementia severity as assessed by Global Clinical Dementia Rating (CDR) plus NACC FTLD

    Time frame: Baseline up to 2 weeks and 3 months

    Global Clinical Dementia Rating (CDR) plus NACC FTLD (score range: min= 0, max= 3, higher score=worse outcome).

  6. Change in aphasia severity as assessed by Progressive Aphasia Severity Scale (PASS)

    Time frame: Baseline up to 2 weeks and 3 months

    PASS is a measure of severity and progression of language deficits in patients with PPA. The scale assesses ten linguistic domains (each score range: min= 0, max= 3): articulation (higher score=worse outcome), fluency (higher score=worse outcome), syntax and grammar (higher score=worse outcome), word retrieval and expression (higher score=worse outcome), repetition (higher score=worse outcome), auditory comprehension (higher score=worse outcome), single word comprehension (higher score=worse outcome), reading (higher score=worse outcome), writing (higher score=worse outcome) and functional communication (higher score=worse outcome). Moreover, it analyzes three supplemental domains (each score range: min= 0, max= 3): initiation of conversation (higher score=worse outcome), turn taking during conversation (higher score=worse outcome) and generation of language (higher score=worse outcome).

  7. Change in functional communication skills as assessed by Lincoln Speech Questionnaire

    Time frame: Baseline up to 2 weeks and 3 months

    Lincoln Speech Questionnaire provides a speech score (score range: min= 0, max= 14, higher score=better outcome) and an understanding score (score range: min= 0, max= 5, higher score=better outcome).

  8. Change in aphasia severity as assessed by Communication Severity Rating Scale (Goodglass and Kaplan)

    Time frame: Baseline up to 2 weeks and 3 months

    Communication Severity Rating Scale (Goodglass and Kaplan): score range: min= 0, max= 5, higher score=better outcome.

  9. Change in depressive symptoms as assessed by Beck Depression Inventory (BDI)

    Time frame: Baseline up to 2 weeks and 3 months

    Beck Depression Inventory (BDI): score range: min= 0, max= 63, higher score=worse outcome

  10. Change in behavior and personality as assessed by Frontal Behavioral Inventory (FBI)

    Time frame: Baseline up to 2 weeks and 3 months

    Frontal Behavioral Inventory (FBI): score range: min= 0, max= 72, higher score=worse outcome.

  11. Change in measure of naming as assessed by Picture Naming subtest from Screening for Aphasia in NeuroDegeneration (SAND)

    Time frame: Baseline up to 2 weeks and 3 months

    Picture Naming subtest from Screening for Aphasia in NeuroDegeneration (SAND) provides total score (score range: min= 0, max= 14, higher score=better outcome), living score (score range: min= 0, max= 7, higher score=better outcome) and non-living score (score range: min= 0, max= 7, higher score=better outcome).

  12. Change in measure of comprehension as assessed by Auditory sentence comprehension subtest from Screening for Aphasia in NeuroDegeneration (SAND)

    Time frame: Baseline up to 2 weeks and 3 months

    Auditory sentence comprehension subtest from Screening for Aphasia in NeuroDegeneration (SAND): total score range: min= 0, max= 8, higher score=better outcome.

  13. Change in measure of comprehension as assessed by Single-word comprehension subtest from Screening for Aphasia in NeuroDegeneration (SAND)

    Time frame: Baseline up to 2 weeks and 3 months

    Single-word comprehension subtest from Screening for Aphasia in NeuroDegeneration (SAND) provides total score (score range: min= 0, max= 12, higher score=better outcome), living score (score range: min= 0, max= 6, higher score=better outcome) and non-living score (score range: min= 0, max= 6, higher score=better outcome).

  14. Change in measure of repetition as assessed by Repetition subtest from Screening for Aphasia in NeuroDegeneration (SAND)

    Time frame: Baseline up to 2 weeks and 3 months

    Repetition subtest from Screening for Aphasia in NeuroDegeneration (SAND) provides total score (score range: min= 0, max= 10, higher score=better outcome), words score (score range: min= 0, max= 6, higher score=better outcome) and non-words score (score range: min= 0, max= 4, higher score=better outcome).

  15. Change in measure of repetition as assessed by Sentence repetition subtest from Screening for Aphasia in NeuroDegeneration (SAND)

    Time frame: Baseline up to 2 weeks and 3 months

    Sentence repetition subtest from Screening for Aphasia in NeuroDegeneration (SAND) provides total score (score range: min= 0, max= 6, higher score=better outcome), predictable sentences score (score range: min= 0, max= 3, higher score=better outcome) and unpredictable sentences score (score range: min= 0, max= 3, higher score=better outcome).

  16. Change in measure of reading as assessed by Reading subtest from Screening for Aphasia in NeuroDegeneration (SAND)

    Time frame: Baseline up to 2 weeks and 3 months

    Reading subtest from Screening for Aphasia in NeuroDegeneration (SAND) provides total score (score range: min= 0, max= 16, higher score=better outcome), words score (score range: min= 0, max= 12, higher score=better outcome) and non-words score (score range: min= 0, max= 4, higher score=better outcome).

  17. Change in measure of writing as assessed by Writing subtest from Screening for Aphasia in NeuroDegeneration (SAND)

    Time frame: Baseline up to 2 weeks and 3 months

    Writing subtest from Screening for Aphasia in NeuroDegeneration (SAND) provides Information Units score (score range: min= 0, max= 6, higher score=better outcome), total number of words score (score range: min= 0, max= no limits, higher score=better outcome), number of nouns/total number of words score (score range: min= 0, max= 1, higher score=better outcome), number of verbs/total number of words (score range: min= 0, max= 1, higher score=better outcome), number of correct syntactic structures/total number of syntactic structures score (score range: min= 0, max= 1, higher score=better outcome), number of orthographic errors score (score range: min= 0, max= no limits, higher score=worse outcome), number of lexico-semantic errors/number of words score (score range: min= 0, max= 1, higher score=worse outcome).

  18. Change in measure of semantics as assessed by Semantic association subtest from Screening for Aphasia in NeuroDegeneration (SAND)

    Time frame: Baseline up to 2 weeks and 3 months

    Semantic association subtest from Screening for Aphasia in NeuroDegeneration (SAND): total score range: min= 0, max= 4, higher score=better outcome.

  19. Change in measure of oral production as assessed by Picture description subtest from Screening for Aphasia in NeuroDegeneration (SAND)

    Time frame: Baseline up to 2 weeks and 3 months

    Picture description subtest from SAND provides Information Units score (score range: min= 0, max= 8, higher score=better outcome), total number of words score (score range: min= 0, max= no limits, higher score=better outcome), number of nouns/total number of words score (score range: min= 0, max= 1, higher score=better outcome), number of verbs/total number of words score (score range: min= 0, max= 1, higher score=better outcome), number of sentences score (score range: min= 0, max= no limits, higher score=better outcome), number of subordinates/number of sentences score (score range: min= 0, max= no limits, higher score=better outcome), number of repaired sequences/number of words score (score range: min= 0, max= 1, higher score=worse outcome), number of phonological errors/number of words (score range: min= 0, max= 1, higher score=worse outcome), number of lexico-semantic errors/number of words (score range: min= 0, max= 1, higher score=worse outcome).

  20. Change in measure of naming as assessed by Subtest from Aachener Aphasie Test (AAT)

    Time frame: Baseline up to 2 weeks and 3 months

    Naming subtest from Aachener Aphasie Test (AAT): score range: min= 0, max= 120, higher score=better outcome.

  21. Change in measure of object naming as assessed by Subtest from Battery for the Assessment of Aphasic Disorders (BADA)

    Time frame: Baseline up to 2 weeks and 3 months

    Subtest from Battery for the Assessment of Aphasic Disorders (BADA): score range: min= 0, max= 30, higher score=better outcome.

  22. Change in measure of fluency abilities as assessed by Verbal Fluency (semantic and phonemic)

    Time frame: Baseline up to 2 weeks and 3 months

    Verbal Fluency (semantic and phonemic): score range min= 0, max= no limits, higher score=better outcome.

  23. Change in measure of constructional praxia as assessed by Rey-Osterrieth Complex Figure-Copy

    Time frame: Baseline up to 2 weeks and 3 months

    Rey-Osterrieth Complex Figure-Copy: score range min= 0, max= 36, higher score=better outcome.

  24. Change in measure of verbal long-term memory as assessed by Story Recall

    Time frame: Baseline up to 2 weeks and 3 months

    Story Recall: score range min= 0, max= 28, higher score=better outcome.

  25. Change in measure of nonverbal long-term memory as assessed by Rey-Osterrieth Complex Figure-Recall

    Time frame: Baseline up to 2 weeks and 3 months

    Rey-Osterrieth Complex Figure-Recall: score range min= 0, max= 36, higher score=better outcome.

  26. Change in measure of attentional abilities as assessed by Trial Making Test

    Time frame: Baseline up to 2 weeks and 3 months

    Trial Making Test: score range: min= n/a, max= no limits, higher score=worse outcome.

  27. Change in measure of executive abilities as assessed by Stroop Test

    Time frame: Baseline up to 2 weeks and 3 months

    Stroop Test: score range: min= n/a, max= no limits, higher score=worse outcome.

  28. Change in measure of global cognitive impairment as assessed by Mini Mental State Examination (MMSE)

    Time frame: Baseline up to 2 weeks and 3 months

    Mini Mental State Examination (MMSE): score range: min= 0, max= 30, higher score=better outcome.

  29. Change in molecular biomarkers as assessed by the size and the concentration of plasma Extracellular vesicles (EVs)

    Time frame: Baseline up to 2 weeks

    Size and the concentration of plasma EVs

  30. Change in molecular biomarkers as assessed by Neurofilament light chain (NFL) levels

    Time frame: Baseline up to 2 weeks

    Neurofilament light chain (NFL) levels

  31. Change in molecular biomarkers as assessed by Glial Fibrillary Acidic Protein (GFAP) levels

    Time frame: Baseline up to 2 weeks

    Glial Fibrillary Acidic Protein (GFAP) levels

  32. Change in molecular biomarkers as assessed by brain-derived neurotrophic factor (BDNF)

    Time frame: Baseline up to 2 weeks

    Brain-derived neurotrophic factor (BDNF) levels

  33. Change in molecular biomarkers as assessed by neurogranin levels

    Time frame: Baseline up to 2 weeks

    Neurogranin levels

  34. Change in functional connectivity as derived from resting-state functional MRI

    Time frame: Baseline up to 2 weeks

    Functional connectivity as derived from resting-state functional MRI

  35. Change in structural connectivity as derived from diffusion-weighted MRI

    Time frame: Baseline up to 2 weeks

    Structural connectivity as derived from diffusion-weighted MRI

Study contacts

Contact information is provided by the study sponsor or research team.

Maria Cotelli

CONTACT

[email protected]

00390303501457

Sponsors and collaborators

Lead sponsor

IRCCS Centro San Giovanni di Dio Fatebenefratelli

Other

Collaborators

  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
  • Fondazione Regionale per la Ricerca Biomedica
  • IRCCS Fondazione Don Carlo Gnocchi - ONLUS, Milan
  • IRCCS National Neurological Institute "C. Mondino" Foundation

Registry information

Acronym: MAINSTREAM

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Feb 15, 2023
Registry last updated
Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.